Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weidong Han

Showing results (341-350 of 392) with videos related to

Pageof 40
Sort By:
Cancer Science|August 27, 2021
Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinomaHongming Pan, Huanqing Cheng, Huina Wang, et al.
Nature Communications|August 13, 2024
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trialLiang Dong, Zhi Cao, Meixia Chen, et al.
The Journal of Clinical Investigation|May 12, 2015
MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipidsXianghui Fu, Bingning Dong, Yan Tian, et al.
Cell Reports. Medicine|December 10, 2024
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic stateXingying Zhang, Chenze Zhang, Shan Lu, et al.
International Journal of Cancer|April 18, 2018
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancerMeixia Chen, Jing Nie, Yang Liu, et al.
Journal of Hematology & Oncology|April 5, 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemiaHanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Blood|June 20, 2020
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphomaChuan Tong, Yajing Zhang, Yang Liu, et al.
Journal of Hematology & Oncology|May 20, 2020
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemiaHanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Signal Transduction and Targeted Therapy|March 18, 2026
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signalingXinran Ma, Yang Zhang, Yao Wang, et al.
Therapeutic Advances in Medical Oncology|April 7, 2023
A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignanciesDa Li, Hong Pan, Wei Wang, et al.
Pageof 40

Showing results (341-350 of 392) with videos related to

Sort By:
Pageof 40
Cancer Science|August 27, 2021
Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinomaHongming Pan, Huanqing Cheng, Huina Wang, et al.
Nature Communications|August 13, 2024
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trialLiang Dong, Zhi Cao, Meixia Chen, et al.
The Journal of Clinical Investigation|May 12, 2015
MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipidsXianghui Fu, Bingning Dong, Yan Tian, et al.
Cell Reports. Medicine|December 10, 2024
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic stateXingying Zhang, Chenze Zhang, Shan Lu, et al.
International Journal of Cancer|April 18, 2018
Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancerMeixia Chen, Jing Nie, Yang Liu, et al.
Journal of Hematology & Oncology|April 5, 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemiaHanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Blood|June 20, 2020
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphomaChuan Tong, Yajing Zhang, Yang Liu, et al.
Journal of Hematology & Oncology|May 20, 2020
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemiaHanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Signal Transduction and Targeted Therapy|March 18, 2026
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signalingXinran Ma, Yang Zhang, Yao Wang, et al.
Therapeutic Advances in Medical Oncology|April 7, 2023
A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignanciesDa Li, Hong Pan, Wei Wang, et al.
Pageof 40